The promise and perils of biomarker testing in gynecologic cancers
•Biomarker testing is crucial for personalized medicine, offering benefits in treatment precision, prognosis and outcomes.•Overcoming barriers to biomarker testing utilization is essential for equitable access and optimal care for all patients.•Implementing policy change, clinical pathways, and educ...
Uložené v:
| Vydané v: | Gynecologic oncology Ročník 201; s. 53 - 55 |
|---|---|
| Hlavní autori: | , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
Elsevier Inc
01.10.2025
|
| Predmet: | |
| ISSN: | 0090-8258, 1095-6859, 1095-6859 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | •Biomarker testing is crucial for personalized medicine, offering benefits in treatment precision, prognosis and outcomes.•Overcoming barriers to biomarker testing utilization is essential for equitable access and optimal care for all patients.•Implementing policy change, clinical pathways, and educational programs can enhance the effective use of biomarker testing. |
|---|---|
| AbstractList | Highlights•Biomarker testing is crucial for personalized medicine, offering benefits in treatment precision, prognosis and outcomes. •Overcoming barriers to biomarker testing utilization is essential for equitable access and optimal care for all patients. •Implementing policy change, clinical pathways, and educational programs can enhance the effective use of biomarker testing. •Biomarker testing is crucial for personalized medicine, offering benefits in treatment precision, prognosis and outcomes.•Overcoming barriers to biomarker testing utilization is essential for equitable access and optimal care for all patients.•Implementing policy change, clinical pathways, and educational programs can enhance the effective use of biomarker testing. |
| Author | Previs, Rebecca A. Fitch, Katherine C. Moss, Haley A. |
| Author_xml | – sequence: 1 givenname: Katherine C. surname: Fitch fullname: Fitch, Katherine C. organization: Duke University Medical Center, Duke Cancer Institute, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Durham, NC, USA – sequence: 2 givenname: Rebecca A. surname: Previs fullname: Previs, Rebecca A. organization: Duke University Medical Center, Duke Cancer Institute, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Durham, NC, USA – sequence: 3 givenname: Haley A. surname: Moss fullname: Moss, Haley A. email: haley.moss@duke.edu organization: Duke University Medical Center, Duke Cancer Institute, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Durham, NC, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40812118$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUU1PGzEUtBCoBOgvQKp87GW3z3a8awtRiaJ-SUgcgLPl2G9Th40d7KRS_n0dQntAqjj5SZ6ZNzPvhBzGFJGQcwYtA9Z9WrTb-TamlgOXLfQtMH1AJgy0bDol9SGZAGhoFJfqmJyUsgAAAYy_I8dTUIwzpibky_0vpKuclqEgtdHTFeYwFpoGOgtpafMjZrrGsg5xTkOkdSO6NKZ5cNTZ6DCXM3I02LHg-5f3lDx8-3p__aO5uf3-8_rqpnFi2q0bIYdp7wRY3Uk-G3pUPUOnrEXhcODaM-HtdCa1dMLXH29Fp7jXmg81glbilHzc61a7T5tqyVTTDsfRRkybYgQXuley412FfniBbmZL9GaVQ42yNX9zV4DYA1xOpWQc_kEYmF27ZmGe2zW7dg30prZbWZd7FtaYvwNmU1zAWoIPGd3a-BTe4H9-xXdjiMHZ8RG3WBZpk2Nt0DBTuAFzt7vf7nxc1olrVgUu_i_w5vo_Mz2sMw |
| Cites_doi | 10.1038/s41698-025-00876-y 10.1200/JCO.19.02105 10.1016/j.ygyno.2021.08.027 10.1016/j.ygyno.2021.10.071 10.1056/NEJMoa2216334 10.1038/modpathol.2016.117 10.1016/j.ajog.2022.08.043 10.1001/jamaoncol.2020.4515 10.1001/jamaoncol.2015.3638 10.1056/NEJMoa2309169 10.1038/nature12113 10.1002/ijgo.14923 10.1016/j.ygyno.2022.10.024 10.1001/jamanetworkopen.2024.19142 10.1200/JCO.21.02767 10.1016/j.ygyno.2023.04.010 10.1136/ijgc-2022-004142 10.1038/modpathol.2016.186 |
| ContentType | Journal Article |
| Copyright | 2025 |
| Copyright_xml | – notice: 2025 |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1016/j.ygyno.2025.07.019 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1095-6859 |
| EndPage | 55 |
| ExternalDocumentID | 40812118 10_1016_j_ygyno_2025_07_019 S0090825825009291 1_s2_0_S0090825825009291 |
| Genre | Editorial Commentary |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9DU 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACLOT ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CAG COF CS3 DM4 DU5 EBS EFBJH EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LG5 M29 M41 MO0 N9A O-L O9- OAUVE OQ. OZT P-8 P-9 P2P PC. PH~ Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SES SEW SPCBC SSH SSZ T5K UDS UHS UV1 WUQ X7M XPP Z5R ZGI ZMT ZU3 ZXP ~G- ~HD AAYXX CITATION ACRLP AHHHB BNPGV NPM 7X8 |
| ID | FETCH-LOGICAL-c346t-35f47c30a9652bf7e871ec8aae3cef29d13da4b595c3d1ecda3682d992f825983 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001584444700002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0090-8258 1095-6859 |
| IngestDate | Thu Oct 02 21:50:50 EDT 2025 Sat Nov 08 03:22:32 EST 2025 Sat Nov 29 06:55:02 EST 2025 Sat Nov 29 17:08:55 EST 2025 Sat Nov 29 12:11:11 EST 2025 Sat Nov 29 06:56:16 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c346t-35f47c30a9652bf7e871ec8aae3cef29d13da4b595c3d1ecda3682d992f825983 |
| Notes | SourceType-Scholarly Journals-1 content type line 23 ObjectType-Editorial-2 ObjectType-Commentary-1 |
| PMID | 40812118 |
| PQID | 3239785626 |
| PQPubID | 23479 |
| PageCount | 3 |
| ParticipantIDs | proquest_miscellaneous_3239785626 pubmed_primary_40812118 crossref_primary_10_1016_j_ygyno_2025_07_019 elsevier_sciencedirect_doi_10_1016_j_ygyno_2025_07_019 elsevier_clinicalkeyesjournals_1_s2_0_S0090825825009291 elsevier_clinicalkey_doi_10_1016_j_ygyno_2025_07_019 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-10-01 |
| PublicationDateYYYYMMDD | 2025-10-01 |
| PublicationDate_xml | – month: 10 year: 2025 text: 2025-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Gynecologic oncology |
| PublicationTitleAlternate | Gynecol Oncol |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Chakravarty, Johnson, Sklar (bb0005) 2022; 40 The Cancer Genome Atlas Research Network, Kandoth, Schultz (bb0035) 2013; 497 National Comprehensive Cancer Network (bb0075) 2025 Oaknin, Tinker, Gilbert (bb0050) 2020; 6 Scheel, Dietel, Heukamp (bb0085) 2016; 29 Sabbagh, Herran, Hijazi (bb0125) 2024; 7 National Comprehensive Cancer Network (bb0065) 2025 McLaughlin, Han, Schalper (bb0080) 2016; 2 Group PS (bb0115) 2025 Smith, Alvarez, Heintz, Haggerty, Ko (bb0130) 2023; 228 (bb0060) June 2025 Bruno, Hess, Li, Su, Patel (bb0120) 2022; 6 Mirza, Chase, Slomovitz (bb0040) 2023; 388 (bb0100) 2024 Orellana, Kim, Beriwal (bb0105) 2022; 164 Berek, Matias-Guiu, Creutzberg (bb0025) 2023; 162 Walsh, Hacker, Secord, DeLair, McCourt, Urban (bb0030) 2023; 168 Marabelle, Le, Ascierto (bb0045) 2020; 38 Karpel, Manderski, Pothuri (bb0020) 2023; 33 National Comprehensive Cancer Network (bb0055) March 5, 2025 Somasegar, Hoppenot, Kuchta (bb0015) 2021; 163 Rehman, Han, Carvajal-Hausdorf (bb0090) 2017; 30 Moore, Angelergues, Konecny (bb0095) 2023; 389 Orellana, Kim, Beriwal, Taylor, Smith, Lesnock (bb0110) 2023; 173 Bartolomucci, Nobrega, Ferrier (bb0070) 2025; 9 Gibbs, Peneva, Cuyun Carter (bb0010) 2023; 7 The Cancer Genome Atlas Research Network (10.1016/j.ygyno.2025.07.019_bb0035) 2013; 497 Karpel (10.1016/j.ygyno.2025.07.019_bb0020) 2023; 33 McLaughlin (10.1016/j.ygyno.2025.07.019_bb0080) 2016; 2 Sabbagh (10.1016/j.ygyno.2025.07.019_bb0125) 2024; 7 Marabelle (10.1016/j.ygyno.2025.07.019_bb0045) 2020; 38 Somasegar (10.1016/j.ygyno.2025.07.019_bb0015) 2021; 163 Gibbs (10.1016/j.ygyno.2025.07.019_bb0010) 2023; 7 Walsh (10.1016/j.ygyno.2025.07.019_bb0030) 2023; 168 Orellana (10.1016/j.ygyno.2025.07.019_bb0105) 2022; 164 Berek (10.1016/j.ygyno.2025.07.019_bb0025) 2023; 162 Bartolomucci (10.1016/j.ygyno.2025.07.019_bb0070) 2025; 9 Rehman (10.1016/j.ygyno.2025.07.019_bb0090) 2017; 30 Chakravarty (10.1016/j.ygyno.2025.07.019_bb0005) 2022; 40 National Comprehensive Cancer Network (10.1016/j.ygyno.2025.07.019_bb0075) 2025 National Comprehensive Cancer Network (10.1016/j.ygyno.2025.07.019_bb0065) 2025 Moore (10.1016/j.ygyno.2025.07.019_bb0095) 2023; 389 Bruno (10.1016/j.ygyno.2025.07.019_bb0120) 2022; 6 Scheel (10.1016/j.ygyno.2025.07.019_bb0085) 2016; 29 Oaknin (10.1016/j.ygyno.2025.07.019_bb0050) 2020; 6 Smith (10.1016/j.ygyno.2025.07.019_bb0130) 2023; 228 National Comprehensive Cancer Network (10.1016/j.ygyno.2025.07.019_bb0055) (10.1016/j.ygyno.2025.07.019_bb0100) 2024 Orellana (10.1016/j.ygyno.2025.07.019_bb0110) 2023; 173 Mirza (10.1016/j.ygyno.2025.07.019_bb0040) 2023; 388 Group PS (10.1016/j.ygyno.2025.07.019_bb0115) |
| References_xml | – volume: 40 start-page: 1231 year: 2022 end-page: 1258 ident: bb0005 article-title: Somatic genomic testing in patients with metastatic or advanced Cancer: ASCO provisional clinical opinion publication-title: J. Clin. Oncol. – volume: 33 start-page: 1044 year: 2023 end-page: 1050 ident: bb0020 article-title: Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort publication-title: Int. J. Gynecol. Cancer – volume: 228 start-page: 98 year: 2023 end-page: 100 e1 ident: bb0130 article-title: Disparities in biomarker testing in ovarian cancer: a real-world analysis publication-title: Am. J. Obstet. Gynecol. – year: June 2025 ident: bb0060 article-title: Important Prescribing Information: ZEJULA (niraparib) – volume: 164 start-page: 129 year: 2022 end-page: 135 ident: bb0105 article-title: Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer publication-title: Gynecol. Oncol. – volume: 38 start-page: 1 year: 2020 end-page: 10 ident: bb0045 article-title: Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient Cancer: results from the phase II KEYNOTE-158 study publication-title: J. Clin. Oncol. – volume: 388 start-page: 2145 year: 2023 end-page: 2158 ident: bb0040 article-title: Dostarlimab for primary advanced or recurrent endometrial Cancer publication-title: N. Engl. J. Med. – year: 2025 ident: bb0065 article-title: Uterine Neoplasms – volume: 9 start-page: 84 year: 2025 ident: bb0070 article-title: Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology publication-title: NPJ Precis. Oncol. – volume: 2 start-page: 46 year: 2016 end-page: 54 ident: bb0080 article-title: Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer publication-title: JAMA Oncol. – volume: 497 start-page: 67 year: 2013 end-page: 73 ident: bb0035 article-title: Integrated genomic characterization of endometrial carcinoma publication-title: Nature – volume: 7 year: 2023 ident: bb0010 article-title: Comprehensive review on the clinical impact of next-generation sequencing tests for the Management of Advanced Cancer publication-title: JCO Precis. Oncol. – volume: 162 start-page: 383 year: 2023 end-page: 394 ident: bb0025 article-title: FIGO staging of endometrial cancer: 2023 publication-title: Int. J. Gynaecol. Obstet. – year: March 5, 2025 ident: bb0055 article-title: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) – year: 2025 ident: bb0115 article-title: Press Release: Phase III Trial Shows Molecular Profiling Can Safely Reduce Radiation for Women with Endometrial Cancer and Optimise Treatment for Patients at a Higher Risk European Society for Radiotherapy may 5 – volume: 7 year: 2024 ident: bb0125 article-title: Biomarker testing disparities in metastatic colorectal Cancer publication-title: JAMA Netw. Open – volume: 173 start-page: 81 year: 2023 end-page: 87 ident: bb0110 article-title: Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer publication-title: Gynecol. Oncol. – year: 2024 ident: bb0100 publication-title: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer – volume: 29 start-page: 1165 year: 2016 end-page: 1172 ident: bb0085 article-title: Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas publication-title: Mod. Pathol. – volume: 168 start-page: 48 year: 2023 end-page: 55 ident: bb0030 article-title: Molecular testing for endometrial cancer: An SGO clinical practice statement publication-title: Gynecol. Oncol. – volume: 389 start-page: 2162 year: 2023 end-page: 2174 ident: bb0095 article-title: Mirvetuximab Soravtansine in FRalpha-positive, platinum-resistant ovarian cancer publication-title: N. Engl. J. Med. – year: 2025 ident: bb0075 article-title: Cervical Cancer – volume: 163 start-page: 220 year: 2021 end-page: 228 ident: bb0015 article-title: Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers publication-title: Gynecol. Oncol. – volume: 6 start-page: 1766 year: 2020 end-page: 1772 ident: bb0050 article-title: Clinical activity and safety of the anti-programmed death 1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial Cancer: a nonrandomized phase 1 clinical trial publication-title: JAMA Oncol. – volume: 6 year: 2022 ident: bb0120 article-title: Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States publication-title: JCO Precis. Oncol. – volume: 30 start-page: 340 year: 2017 end-page: 349 ident: bb0090 article-title: Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer publication-title: Mod. Pathol. – year: 2025 ident: 10.1016/j.ygyno.2025.07.019_bb0065 – volume: 9 start-page: 84 issue: 1 year: 2025 ident: 10.1016/j.ygyno.2025.07.019_bb0070 article-title: Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology publication-title: NPJ Precis. Oncol. doi: 10.1038/s41698-025-00876-y – volume: 6 year: 2022 ident: 10.1016/j.ygyno.2025.07.019_bb0120 article-title: Disparities in biomarker testing and clinical trial enrollment among patients with lung, breast, or colorectal cancers in the United States publication-title: JCO Precis. Oncol. – volume: 38 start-page: 1 issue: 1 year: 2020 ident: 10.1016/j.ygyno.2025.07.019_bb0045 article-title: Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient Cancer: results from the phase II KEYNOTE-158 study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.19.02105 – volume: 163 start-page: 220 issue: 2 year: 2021 ident: 10.1016/j.ygyno.2025.07.019_bb0015 article-title: Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2021.08.027 – volume: 164 start-page: 129 issue: 1 year: 2022 ident: 10.1016/j.ygyno.2025.07.019_bb0105 article-title: Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2021.10.071 – ident: 10.1016/j.ygyno.2025.07.019_bb0115 – volume: 388 start-page: 2145 issue: 23 year: 2023 ident: 10.1016/j.ygyno.2025.07.019_bb0040 article-title: Dostarlimab for primary advanced or recurrent endometrial Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2216334 – volume: 29 start-page: 1165 issue: 10 year: 2016 ident: 10.1016/j.ygyno.2025.07.019_bb0085 article-title: Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas publication-title: Mod. Pathol. doi: 10.1038/modpathol.2016.117 – volume: 228 start-page: 98 issue: 1 year: 2023 ident: 10.1016/j.ygyno.2025.07.019_bb0130 article-title: Disparities in biomarker testing in ovarian cancer: a real-world analysis publication-title: Am. J. Obstet. Gynecol. doi: 10.1016/j.ajog.2022.08.043 – year: 2025 ident: 10.1016/j.ygyno.2025.07.019_bb0075 – volume: 6 start-page: 1766 issue: 11 year: 2020 ident: 10.1016/j.ygyno.2025.07.019_bb0050 article-title: Clinical activity and safety of the anti-programmed death 1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial Cancer: a nonrandomized phase 1 clinical trial publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2020.4515 – volume: 2 start-page: 46 issue: 1 year: 2016 ident: 10.1016/j.ygyno.2025.07.019_bb0080 article-title: Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2015.3638 – volume: 389 start-page: 2162 issue: 23 year: 2023 ident: 10.1016/j.ygyno.2025.07.019_bb0095 article-title: Mirvetuximab Soravtansine in FRalpha-positive, platinum-resistant ovarian cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2309169 – volume: 497 start-page: 67 issue: 7447 year: 2013 ident: 10.1016/j.ygyno.2025.07.019_bb0035 article-title: Integrated genomic characterization of endometrial carcinoma publication-title: Nature doi: 10.1038/nature12113 – volume: 7 year: 2023 ident: 10.1016/j.ygyno.2025.07.019_bb0010 article-title: Comprehensive review on the clinical impact of next-generation sequencing tests for the Management of Advanced Cancer publication-title: JCO Precis. Oncol. – volume: 162 start-page: 383 issue: 2 year: 2023 ident: 10.1016/j.ygyno.2025.07.019_bb0025 article-title: FIGO staging of endometrial cancer: 2023 publication-title: Int. J. Gynaecol. Obstet. doi: 10.1002/ijgo.14923 – volume: 168 start-page: 48 year: 2023 ident: 10.1016/j.ygyno.2025.07.019_bb0030 article-title: Molecular testing for endometrial cancer: An SGO clinical practice statement publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2022.10.024 – volume: 7 issue: 7 year: 2024 ident: 10.1016/j.ygyno.2025.07.019_bb0125 article-title: Biomarker testing disparities in metastatic colorectal Cancer publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2024.19142 – volume: 40 start-page: 1231 issue: 11 year: 2022 ident: 10.1016/j.ygyno.2025.07.019_bb0005 article-title: Somatic genomic testing in patients with metastatic or advanced Cancer: ASCO provisional clinical opinion publication-title: J. Clin. Oncol. doi: 10.1200/JCO.21.02767 – ident: 10.1016/j.ygyno.2025.07.019_bb0055 – volume: 173 start-page: 81 year: 2023 ident: 10.1016/j.ygyno.2025.07.019_bb0110 article-title: Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2023.04.010 – volume: 33 start-page: 1044 issue: 7 year: 2023 ident: 10.1016/j.ygyno.2025.07.019_bb0020 article-title: Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort publication-title: Int. J. Gynecol. Cancer doi: 10.1136/ijgc-2022-004142 – year: 2024 ident: 10.1016/j.ygyno.2025.07.019_bb0100 – volume: 30 start-page: 340 issue: 3 year: 2017 ident: 10.1016/j.ygyno.2025.07.019_bb0090 article-title: Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer publication-title: Mod. Pathol. doi: 10.1038/modpathol.2016.186 |
| SSID | ssj0003012 |
| Score | 2.4756732 |
| Snippet | •Biomarker testing is crucial for personalized medicine, offering benefits in treatment precision, prognosis and outcomes.•Overcoming barriers to biomarker... Highlights•Biomarker testing is crucial for personalized medicine, offering benefits in treatment precision, prognosis and outcomes. •Overcoming barriers to... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 53 |
| SubjectTerms | Hematology, Oncology, and Palliative Medicine Obstetrics and Gynecology |
| Title | The promise and perils of biomarker testing in gynecologic cancers |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0090825825009291 https://www.clinicalkey.es/playcontent/1-s2.0-S0090825825009291 https://dx.doi.org/10.1016/j.ygyno.2025.07.019 https://www.ncbi.nlm.nih.gov/pubmed/40812118 https://www.proquest.com/docview/3239785626 |
| Volume | 201 |
| WOSCitedRecordID | wos001584444700002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1095-6859 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003012 issn: 0090-8258 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELagRYgL4s0WWhmJ25Iq9TM-LlUfPFohUdDeLK_joO0hW23Sqv33jGM73dXS8pC4RCtbXifzTcYzzsxnhN7mgqjCCppVjJcZs45mE2JoJhwRnFklTXfW4ffP8vi4GI_Vl3jcUdMdJyDruri8VGf_FWpoA7B96exfwN3_KTTAbwAdrgA7XP8YeDCLgF_4MuCpjANFsi-199k482HruTVCMcuPq9rZYAF9BpiNGfHJYT1Y6J7VdmkTfn_ahoOkPqUywuHudm9rff5ws4DgcNT3HcWj2g-9k5ra49YD4X0SW9wPSzUxSymb4LT54vRAyJ5sLInDgpUM9MBxvQ0svSuWPGwqnG5fgRh8kSbhHclqtK_LFNlf_Zx-SvDncvD3IBpeJ5IrsHLrow9744_92gzmLPDHx3tMPFRdxt_KVDf5KjfFIp1PcvIIPYzBBB4FJXiM7rj6Cbp_FNMlnqL3oAs46gIGXcBBF_Cswr0u4KgLeFrjBV3AUReeoW_7eye7h1k8NCOzlIk2o7xi0tLcKMHJpJIOImJnC2Mcta4iqtyhpWETrrilJfSUhoqClEqRCgSiCvocrdWz2r1EWJZ5JahkpoKo2-bUsApsdCkslYQTwwboXRKPPgvcKDolDZ7qTpraS1PnUoM0B4glEepU9gsLlQbEbx8mfzXMNfGda_SObojO9YoWDJDoR0Z_MviJv5_yTUJYA0L-E5qp3ey80ZSA_15AzCAG6EWAvn90Bt41gXh949-e8xV6cP2OvUZr7fzcbaJ79qKdNvMtdFeOi62ozj8BeCWuIQ |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+promise+and+perils+of+biomarker+testing+in+gynecologic+cancers&rft.jtitle=Gynecologic+oncology&rft.au=Fitch%2C+Katherine+C.&rft.au=Previs%2C+Rebecca+A.&rft.au=Moss%2C+Haley+A.&rft.date=2025-10-01&rft.pub=Elsevier+Inc&rft.issn=0090-8258&rft.volume=201&rft.spage=53&rft.epage=55&rft_id=info:doi/10.1016%2Fj.ygyno.2025.07.019&rft.externalDocID=S0090825825009291 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00908258%2FS0090825825X00093%2Fcov150h.gif |